Cargando…

Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata

AIMS: In older patients, guideline‐directed medical therapy (GDMT) for heart failure (HF) with reduced ejection fraction (<40%; HFrEF) is not contraindicated, but adherence to guidelines is limited. We investigated the implementation of GDMT in HFrEF across different age strata in a large nationw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stolfo, Davide, Lund, Lars H., Becher, Peter Moritz, Orsini, Nicola, Thorvaldsen, Tonje, Benson, Lina, Hage, Camilla, Dahlström, Ulf, Sinagra, Gianfranco, Savarese, Gianluigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd. 2022
Materias:	TREATMENT OF HFrEF
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546348/ https://www.ncbi.nlm.nih.gov/pubmed/35278267 http://dx.doi.org/10.1002/ejhf.2483

Ejemplares similares

Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial
por: Voors, Adriaan A., et al.
Publicado: (2020)

Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction
por: Kramer, Frank, et al.
Publicado: (2020)

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
por: McDowell, Kirsty, et al.
Publicado: (2022)

The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta‐analysis of COMPANION and CARE‐HF
por: Cleland, John G.F., et al.
Publicado: (2022)

Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multicentre trial
por: Cooper, Trond J., et al.
Publicado: (2022)

Persistent High Burden of Heart Failure Across the Ejection Fraction Spectrum in a Nationwide Setting
por: Stolfo, Davide, et al.
Publicado: (2022)

Current and future use of neuromodulation in heart failure( )
por: Duncker, David, et al.
Publicado: (2022)

Neuromodulation in heart failure( )
por: Zannad, Faiez
Publicado: (2022)

Neuromodulation devices for heart failure( )
por: Dusi, Veronica, et al.
Publicado: (2022)

Sympathetic activation in heart failure( )
por: Gronda, E, et al.
Publicado: (2022)

The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?
por: Docherty, Kieran F, et al.
Publicado: (2022)

Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe
por: Marx, Nikolaus, et al.
Publicado: (2022)

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction
por: Stolfo, Davide, et al.
Publicado: (2023)

Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction
por: Chandramouli, Chanchal, et al.
Publicado: (2022)

Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction
por: Uijl, Alicia, et al.
Publicado: (2021)

Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS‐HFpEF study
por: Venkateshvaran, Ashwin, et al.
Publicado: (2022)

Heart failure with mid-range or mildly reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2021)

Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction
por: Stolfo, Davide, et al.
Publicado: (2022)

Dear colleagues: enough with the men-only author panels
por: Van Spall, Harriette G C, et al.
Publicado: (2022)

Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Time for change
por: Zieroth, Shelley, et al.
Publicado: (2022)

Representation matters: a call for inclusivity and equity in heart failure clinical trials
por: Reza, Nosheen, et al.
Publicado: (2022)

A rationale for dedicated trials of combination therapy in heart failure
por: Blumer, Vanessa, et al.
Publicado: (2022)

Getting ahead of the game: in-hospital initiation of HFrEF therapies
por: Biegus, Jan, et al.
Publicado: (2022)

Reflecting on the advancements of HFrEF therapies over the last two decades and predicting what is yet to come
por: Piña, Ileana L, et al.
Publicado: (2022)

Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction
por: Fukuta, Hidekatsu
Publicado: (2020)

Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives
por: van Woerden, Gijs, et al.
Publicado: (2022)

Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF)
por: Linde, Cecilia, et al.
Publicado: (2022)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction
por: Teramoto, Kanako, et al.
Publicado: (2022)

Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis
por: Bilak, Joanna M, et al.
Publicado: (2022)

Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology
por: Guazzi, Marco, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
por: Gori, Mauro, et al.
Publicado: (2022)

Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?
por: Deschaine, Brent, et al.
Publicado: (2022)

Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real‐world data from the Swedish Heart Failure Registry
por: Savarese, G., et al.
Publicado: (2020)

What causes exertional dyspnoea in patients with atrial fibrillation? Implications for catheter ablation in patients with heart failure
por: Packer, Milton
Publicado: (2021)

Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry
por: Lindberg, Felix, et al.
Publicado: (2022)

Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry
por: Kapelios, Chris J, et al.
Publicado: (2021)

Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
por: Stolfo, Davide, et al.
Publicado: (2019)

Association between heart failure quality of care and mortality: a population‐based cohort study using nationwide registries
por: Batra, Gorav, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r4th1civpsotv9k75iv7ikfc03